MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium

Matthew F. Buas1,*, Lynn Onstad1, David M. Levine2, Harvey A. Risch3, Wong-Ho Chow4, Geoffrey Liu5, Rebecca C. Fitzgerald6, Leslie Bernstein7, Weimin Ye8, Nigel C. Bird9, Yvonne Romero10,11, Alan G. Casson12, Douglas A. Corley13,14, Nicholas J. Shaheen15, Anna H. Wu16, Marilie D. Gammon17, Brian J. Reid1,18, Laura J. Hardie19, Ulrike Peters1,20*, David C. Whiteman21, Thomas L. Vaughan1,20*

1 Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 2 Department of Biostatistics, University of Washington, School of Public Health, Seattle, Washington, United States of America, 3 Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, United States of America, 4 Department of Epidemiology, MD Anderson Cancer Center, Houston, TX, United States of America, 5 Pharmacogenomic Epidemiology, Ontario Cancer Institute, Toronto, Ontario, Canada, M5G 2M9, 6 Medical Research Council (MRC) Cancer Cell Unit, Hutchison-MRC Research Centre and University of Cambridge, Cambridge, United Kingdom, 7 Department of Populations Sciences, Beckman Research Institute and City of Hope Comprehensive Cancer Center, Duarte, California, United States of America, 8 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, 9 Department of Oncology, Medical School, University of Sheffield, Sheffield, United Kingdom, 10 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America, 11 The Romero Registry, Mayo Clinic, Rochester, Minnesota, United States of America, 12 Department of Surgery, University of Saskatchewan, Saskatoon, SK, Canada, 13 Division of Research, Kaiser Permanente Northern California, Oakland, California, United States of America, 14 San Francisco Medical Center, Kaiser Permanente Northern California, San Francisco, California, United States of America, 15 Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, University of North Carolina, Chapel Hill, North Carolina, United States of America, 16 Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, United States of America, 17 Department of Epidemiology, University of North Carolina School of Public Health, Chapel Hill, North Carolina, United States of America, 18 Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 19 Division of Epidemiology, University of Leeds, Leeds, United Kingdom, 20 Department of Epidemiology, University of Washington, School of Public Health, Seattle, Washington, United States of America, 21 Cancer Control, QIMR Berghofer Medical Research Institute, Brisbane, Australia

* mbuas@fhcrc.org (MFB); tvbaughan@u.washington.edu (TLV)

Abstract

Incidence of esophageal adenocarcinoma (EA) has increased substantially in recent decades. Multiple risk factors have been identified for EA and its precursor, Barrett’s esophagus (BE), such as reflux, European ancestry, male sex, obesity, and tobacco smoking, and several germline genetic variants were recently associated with disease risk. Using data from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) genome-wide association study (GWAS) of 2,515 EA cases, 3,295 BE cases, and 3,207 controls, we examined single nucleotide polymorphisms (SNPs) that potentially affect the biogenesis or
biological activity of microRNAs (miRNAs), small non-coding RNAs implicated in post-transcriptional gene regulation, and deregulated in many cancers, including EA. Polymorphisms in three classes of genes were examined for association with risk of EA or BE: miRNA biogenesis genes (157 SNPs, 21 genes); miRNA gene loci (234 SNPs, 210 genes); and miRNA-targeted mRNAs (177 SNPs, 158 genes). Nominal associations (P < 0.05) of 29 SNPs with EA risk, and 25 SNPs with BE risk, were observed. None remained significant after correction for multiple comparisons (FDR q > 0.50), and we did not find evidence for interactions between variants analyzed and two risk factors for EA/BE (smoking and obesity).

This analysis provides the most extensive assessment to date of miRNA-related SNPs in relation to risk of EA and BE. While common genetic variants within components of the miRNA biogenesis core pathway appear unlikely to modulate susceptibility to EA or BE, further studies may be warranted to examine potential associations between unassessed variants in miRNA genes and targets with disease risk.

Introduction

Incidence of esophageal adenocarcinoma (EA) in Western countries has risen sharply in recent decades, while median survival remains less than one year [1]. EA typically arises within a columnar metaplastic precursor epithelium known as Barrett’s esophagus (BE). Established risk factors for EA and BE include symptomatic gastroesophageal reflux disease (GERD), European ancestry, male sex, obesity, and tobacco smoking [2]. Less is known about the role of inherited genetic variation and its interplay with environmental factors. Candidate-gene-based studies have associated altered risk of EA or BE with DNA polymorphisms in genes that function in a wide range of biological pathways (inflammation, detoxification, DNA repair, angiogenesis, and apoptosis) [3–13], while a recent linkage-based genetic analysis of sibling pairs provided preliminary evidence for several novel germline mutations [14]. These studies have been limited by small sample sizes and the need for validation. In the last few years, large genome-wide association studies of BE and EA identified multiple SNPs significantly associated with disease risk [15–18], including variants located in three transcription factors, a transcriptional co-activator, and the major histocompatibility complex locus, none of which were previously implicated by candidate-based studies.

A large body of work has established that microRNAs (miRNAs), small non-coding RNAs that function in post-transcriptional gene regulation, act as oncogenes or tumor suppressors in a variety of tissues, and their deregulation can lead to cancer [19,20]. MiRNA gene loci are transcribed by RNA polymerase II to generate primary (pri-) miRNA transcripts, which are then cleaved by the nuclear RNAse DROSHA complex to form stem-loop precursor (pre-) miRNAs. Following nuclear export to the cytoplasm, pre-miRNAs undergo further processing by the DICER complex to generate mature miRNAs, which typically bind to the 3’ untranslated region of target messenger RNAs (mRNAs) and mediate translational repression or RNA degradation. MiRNAs have been linked to inflammatory pathways [21,22], which are likely to play important roles in BE/EA. Changes in miRNA expression have been detected at multiple stages in the development of EA [23–38], and certain miRNAs may be associated with prognosis [33,35].

Many studies have reported associations between miRNA-related SNPs and risk of diverse cancers [39]. These SNPs may reside in a) miRNA biogenesis genes, b) miRNA gene loci, or c)
miRNA-targeted mRNAs. Functional miRNA-related SNPs may affect global miRNA expression levels, processing or expression of individual miRNAs, and miRNA target gene specificity. A previous case-control study of 346 esophageal cancer cases (86% EA) and an equal number of matched controls reported that seven miRNA-related SNPs from a panel of 41 total SNPs tested were associated with altered risk of esophageal carcinoma, with the association of one SNP in the pre-miRNA-423 region remaining statistically significant after correction for multiple comparisons [40]. These SNPs have not been validated in independent study populations or evaluated for potential associations with BE, and it is currently unknown whether additional SNPs in the miRNA pathway may modulate disease risk. Using data from a recent genome-wide association study (GWAS) of 2,515 EA cases, 3,295 BE cases, and 3,207 controls [16], we selected 157 biogenesis pathway SNPs, 234 miRNA SNPs, and 177 mRNA target SNPs and assessed their associations with risks of EA and BE.

Methods

Study population and SNP genotyping

The Barrett’s and Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS) included men and women diagnosed with EA or BE, and control participants pooled from 14 individual studies conducted in Western Europe, Australia, and North America over the past twenty years. Detailed study population characteristics and genotyping protocols have been published [16]. Briefly, all EA and BE case participants were confirmed by histologic examination, and a set of population control individuals was drawn from the included Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) studies to serve as a comparison group for both EA and BE case participants. The current analysis employed a pooled dataset that has been described previously [41], and included all BEAGESS participants, additional BE and EA patients from the UK Barrett’s Esophagus Gene Study and the UK Stomach and Oesophageal Cancer Study (SOCS), respectively [16], and additional controls from a hospital-based case-control study of melanoma conducted at the MD Anderson Cancer Center (Houston, TX) [42]. Genotyping of buffy coat or whole blood DNA from all participants was conducted using the Illumina Omni1M Quad platform, in accordance with standard quality control procedures [43]. All participants gave written informed consent, and this project was approved by the ethics review board of the Fred Hutchinson Cancer Research Center. We selected all unrelated participants with missing genotyping call rates < 2%; thus the final study sample included 2,515 EA cases, 3,295 BE cases, and 3,207 controls. Three control participants were excluded from analyses involving BE cases, because of familial relation to cases.

Selection of miRNA-related SNPs

SNPs selected for this study are located in or near a) miRNA biogenesis genes (+/- 2kb), b) miRNA gene loci (+/- 25bp), or c) predicted or verified mRNA targets of miRNAs (S1 Fig). We excluded from consideration SNPs that failed Illumina quality measures or standard quality control procedures [43]. Specifically, SNPs were excluded if any of the following criteria were satisfied: i) Illumina GenTrain score < 0.6 or cluster separation < 0.4; ii) >5% missing call rate over samples; iii) discordant genotype calls in any pair of duplicate study samples; iv) Mendelian error in either one of the HapMap QC trios or the small number of families identified in the BEACON data; v) significant departure from Hardy-Weinberg Equilibrium (P<10^{-4}); vi) minor allele frequency (MAF) < 1%.

After imposing the above filters, we first identified all available Omni1M SNPs (n = 185) located within fourteen genes in the miRNA biogenesis core pathway (2kb flanking sequences for each gene were also included, using gene boundaries defined in hg19/GRChB37): DDX20,
DGCR8, DICER1, DROSHA, EIF2C1-4, GEMIN4, GW182, PRKRA, RAN, TARBP2, XPO5. Similarly, we identified all available Omni1M SNPs (n = 70) located within 1601 human miRNA precursor sequences (+/- 25bp) deposited in miRBase (version 19). Additional Omni1M SNPs (n = 160) in pairwise linkage disequilibrium (LD) (r² > 0.8) with non-Omni1M dbSNP polymorphisms located within the 1601 miRNA precursors (+/-25bp) were also identified, using 1000 Genomes data for the CEU population via the SNP Annotation and Proxy (SNAP) website (http://www.broadinstitute.org/mpg/snap). In the case of multiple possible Omni1M proxy SNPs, selection was based on maximum \( r^2 \) coefficient followed by minimum distance (bp). Within these two categories of SNPs (biogenesis and miRNA gene loci), LD-based pruning was carried out with pairwise LD data from SNAP, using an \( r^2 \) threshold of 0.8, to reduce the number of redundant tests (126/185 biogenesis SNPs and 229/230 miRNA gene SNPs were retained).

To identify potentially functional SNPs in miRNA-targeted mRNAs, we used a database of polymorphisms predicted to alter miRNA-mRNA regulation [44]. Two filters were imposed to limit the set of SNPs to those most likely to be functional. First, we considered miRNA-mRNA interactions only for miRNAs shown to be expressed in the esophagus at some point in the disease progression from normal squamous epithelium to BE/EA. Based on the union of several published reports [32,34–38], 135 expressed miRNAs were identified (S1 Table). Second, after the previous exclusions, we considered only a subset of miRNA-mRNA interactions (≈3%) that were predicted to be most strongly affected by genetic variants in the target mRNA (ΔS > 0.85, where S is the predicted regulation score for a given miRNA:mRNA pairing). LD-based pruning of these filtered SNPs (n = 175) was performed as described previously (145/175 SNPs were retained).

A literature search was also conducted to identify miRNA-related SNPs shown to be associated with cancer susceptibility (S2 Table) [39,45–67]. Variants not already captured by our selection process were added if available in the Omni1M dataset, or proxy SNPs in high LD were substituted where possible, as indicated (S3 Table). The final set of polymorphisms included 157 biogenesis pathway SNPs (21 genes), 234 miRNA SNPs (210 genes), and 177 target mRNA SNPs (158 genes). Minor and major alleles were reported throughout using the ‘plus’ strand designation.

**Statistical analysis**

Unconditional multivariate logistic regression was used to compute odds ratios for risk of EA or BE associated with a given SNP variant, using an additive model (per-allele), while adjusting for age, sex, and the first four principal components (PCs) derived from principal components analysis (PCA) to account for population stratification by ancestry [41]. Inclusion of the first four PCs was empirical, as described previously in the parent GWAS report [16], and based on assessment of i) the percentage of variance accounted for (S2 Fig) and ii) the observed separation of study participants according to pairwise comparisons of individual principal components (S3 Fig). To correct for multiple comparisons when assessing statistical significance, we used the Bonferroni or Benjamini-Hochberg false-discovery rate (FDR) methods [68,69]. The threshold for Bonferroni significance was \( \alpha = 0.05/568 = 8.80 \times 10^{-5} \). Stratified analyses by body mass index (BMI, kg/m²) and history of cigarette smoking were also conducted, and evidence for interaction was assessed by including a product term in the logistic regression model. Smoking history and BMI were defined categorically in stratified analyses (smoking: ever/never, or pack-years: 0, >0 & <15, 15–29, 30–44, 45+; BMI: <25, 25–29, 30–34, 35+), and continuously (pack-years, BMI) to test for interaction. Statistical analyses were conducted using STATA/SE version 13.1 (College Station, TX).
Results

Characteristics of study participants

The distributions of demographic characteristics among controls, EA cases, and BE cases are shown in Table 1. EA cases were somewhat older (mean age: 65.0 years) and more frequently male (87%) relative to controls (mean age: 58.4 years, 73% male) and BE cases (mean age: 63.0 years, 76% male). Among participants with non-missing data for BMI and smoking history, the percentage reporting ever having smoked cigarettes was higher among EA (75%) and BE (66%) cases than among controls (59%). Heavy smoking (45+ pack years) was more prevalent among EA cases (21%) than among controls (14%) or BE cases (14%), while obesity (BMI 30+) was more prevalent among EA (30%) and BE (37%) cases than among controls (20%).

 Associations of miRNA-related SNPs and risk of EA or BE

Of the 157 biogenesis pathway SNPs, 234 miRNA SNPs, and 177 mRNA target SNPs evaluated in this study (S3 Table), 29 were nominally associated (P<0.05) with risk of EA (Table 2 and S4 Fig), and 25 with risk of BE (Table 3). Three SNPs satisfied P<0.05 in both analyses (EA and BE): RDH8 rs1644730 T>A, miR-3117 rs7526812 T>C, and miR-4467 rs12534337 G>A. For each of these SNPs, the risk estimates for EA and BE were similar and in the same

---

Table 1. Characteristics of controls, EA cases, and BE cases.

|                | Controls (n = 3207) | EA (n = 2515) | BE (n = 3295) |
|----------------|---------------------|---------------|---------------|
| Agea           | n %                 | n %           | n %           |
| <50            | 726 22.6            | 189 7.6       | 449 13.7      |
| 50–59          | 885 27.6            | 547 21.9      | 780 23.7      |
| 60–69          | 963 30.0            | 884 35.4      | 1011 30.7     |
| 70+            | 633 19.7            | 875 35.1      | 1048 31.9     |
| Sex            |                     |               |               |
| Female         | 880 27.4            | 320 12.7      | 806 24.5      |
| Male           | 2327 72.6           | 2195 87.3     | 2489 75.5     |
| BMIA           |                     |               |               |
| <25            | 786 36.3            | 245 24.6      | 425 20.7      |
| 25–29.99       | 944 43.6            | 455 45.7      | 882 42.9      |
| 30–34.99       | 307 14.2            | 201 20.2      | 521 25.3      |
| 35+            | 130 6.0             | 95 9.5        | 230 11.2      |
| Smoking statusa |                    |               |               |
| no             | 889 40.9            | 348 24.7      | 798 33.7      |
| yes            | 1284 59.1           | 1062 75.3     | 1570 66.3     |
| Smoking (p-y)b |                     |               |               |
| none           | 889 41.3            | 348 32.8      | 798 44.5      |
| <15            | 358 16.6            | 156 14.7      | 320 17.9      |
| 15–29          | 326 15.1            | 160 15.1      | 232 12.9      |
| 30–44          | 273 12.7            | 173 16.3      | 198 11.0      |
| 45+            | 309 14.3            | 225 21.2      | 244 13.6      |

aNumbers do not add to total subjects due to missing data
bpack-years
doi:10.1371/journal.pone.0128617.t001
directions (OR 0.88 vs 0.93, 1.14 vs 1.11, 1.28 vs 1.25, respectively) (S4 Table). After correction for multiple comparisons (n = 568 total SNPs), using the Bonferroni or false discovery rate method, none of the observed associations remained statistically significant (FDR q > 0.50).

Table 2. MiRNA-related SNPs and risk of EA.

### Biogenesis pathway

| SNP     | Gene  | Alleles | Controls N | MAF† | EA cases N | MAF‡ | OR*     | 95% CI     | P     | q    |
|---------|-------|---------|------------|------|------------|------|---------|------------|-------|------|
| 1       | kgp1460594 | XPO5 | A/G 3207 | 0.075 | 2495 | 0.091 | 1.21 | (1.05–1.40) | 0.0074 | 0.54 |
| 2       | rs7702984  | DROSHA | G/A 3206 | 0.012 | 2494 | 0.009 | 0.63 | (0.43–0.94) | 0.0227 | 0.70 |
| 3       | rs4351606  | EIF2C3 | A/G 3205 | 0.056 | 2493 | 0.047 | 0.82 | (0.69–0.98) | 0.0327 | 0.84 |

### miRNA genes

| SNP     | Gene  | Alleles | Controls N | MAF† | EA cases N | MAF‡ | OR*     | 95% CI     | P     | q    |
|---------|-------|---------|------------|------|------------|------|---------|------------|-------|------|
| 1       | rs17780825 | miR-4725 | C/T 3206 | 0.020 | 2494 | 0.028 | 1.46 | (1.13–1.89) | 0.0037 | 0.54 |
| 2       | rs1709696  | miR-3612 | A/C 3205 | 0.227 | 2493 | 0.208 | 0.88 | (0.80–0.97) | 0.0086 | 0.54 |
| 3       | rs1378940  | miR-4513 | C/A 3206 | 0.343 | 2495 | 0.314 | 0.89 | (0.82–0.97) | 0.0091 | 0.54 |
| 4       | rs12534337 | miR-4467 | A/G 3205 | 0.042 | 2495 | 0.053 | 1.28 | (1.06–1.55) | 0.0095 | 0.54 |
| 5       | rs12564376 | miR-4421 | A/G 3207 | 0.039 | 2495 | 0.030 | 0.75 | (0.60–0.94) | 0.0108 | 0.55 |

### mRNA targets

| SNP     | Gene  | Alleles | Controls N | MAF† | EA cases N | MAF‡ | OR*     | 95% CI     | P     | q    |
|---------|-------|---------|------------|------|------------|------|---------|------------|-------|------|
| 1       | rs1644730  | RDH8    | A/T 3202 | 0.472 | 2495 | 0.441 | 0.88 | (0.81–0.95) | 0.0011 | 0.54 |
| 2       | rs1045968  | PRRT2   | A/C 3206 | 0.141 | 2494 | 0.160 | 1.17 | (1.05–1.31) | 0.0046 | 0.54 |
| 3       | rs1050629  | MLF2    | A/G 3206 | 0.025 | 2495 | 0.033 | 1.40 | (1.10–1.78) | 0.0055 | 0.54 |
| 4       | rs2075993  | E2F2    | T/C 3206 | 0.197 | 2495 | 0.213 | 1.12 | (1.02–1.24) | 0.0204 | 0.70 |

*Nominal P < 0.05
†Minor/major alleles
‡Minor allele frequency
*OR adjusted for age, sex, PC1-PC4, using additive model (per-allele)
Stratified analyses by smoking history and BMI

Stratified analyses were conducted to determine whether or not selected top candidates listed in Tables 2 & 3 (P < 7.5x10⁻³) exhibited disease-risk associations that varied by pack-years of smoking history or by BMI (S5 and S6 Tables). Assessment of all 568 variants revealed multiple nominally-significant interactions with smoking history or BMI, but none remained significant after correction for multiple comparisons (FDR q > 0.05). One variant (rs595055 T>C) in the biogenesis gene EIF2C1 exhibited a borderline-significant interaction (P = 0.0001,

Table 3. MiRNA-related SNPs and risk of BE.

| SNP       | Gene    | Alleles† | Controls N | MAF‡ | BE cases N | MAF‡ | OR* | 95% CI       | P     | q     |
|-----------|---------|----------|------------|------|------------|------|-----|--------------|-------|-------|
| rs8192593 | TARBP2  | T/C      | 3201       | 0.040| 3286       | 0.034| 0.77|(0.63–0.93)  | 0.0063| 0.89  |
| rs595055  | EIF2C1  | C/T      | 3202       | 0.142| 3288       | 0.125| 0.88|(0.79–0.97)  | 0.0136| 0.89  |
| rs2947620 | EIF2C2  | C/A      | 3198       | 0.199| 3287       | 0.186| 0.90|(0.82–0.98)  | 0.0198| 0.89  |
| rs12741800| LIN28   | A/G      | 3198       | 0.458| 3276       | 0.442| 0.92|(0.86–0.99)  | 0.0231| 0.89  |
| rs11247946| LIN28   | G/A      | 3204       | 0.345| 3288       | 0.327| 0.92|(0.85–0.99)  | 0.0295| 0.89  |
| rs5387779 | DDX20   | A/G      | 3204       | 0.217| 3288       | 0.202| 0.91|(0.83–0.99)  | 0.0323| 0.89  |
| rs6598964 | LIN28   | T/C      | 3204       | 0.368| 3288       | 0.348| 0.93|(0.86–1.00)  | 0.0391| 0.89  |
| rs12044203| EIF2C4  | A/G      | 3194       | 0.021| 3284       | 0.014| 0.75|(0.57–0.99)  | 0.0420| 0.89  |

| SNP       | Gene    | Alleles† | Controls N | MAF‡ | BE cases N | MAF‡ | OR* | 95% CI       | P     | q     |
|-----------|---------|----------|------------|------|------------|------|-----|--------------|-------|-------|
| rs3785722 | miR-1269b| A/G      | 3203       | 0.449| 3288       | 0.422| 0.89|(0.83–0.96)  | 0.0021| 0.89  |
| rs10906086| miR-548ak| C/A      | 3203       | 0.469| 3286       | 0.490| 1.10|(1.03–1.19)  | 0.007 | 0.89  |
| rs7000768 | miR-3686 | G/A      | 3204       | 0.304| 3288       | 0.325| 1.11|(1.02–1.19)  | 0.0104| 0.89  |
| rs12534337| miR-4467 | A/G      | 3202       | 0.042| 3287       | 0.052| 1.25|(1.05–1.48)  | 0.0106| 0.89  |
| rs10862193| miR-617  | G/A      | 3200       | 0.428| 3281       | 0.409| 0.92|(0.86–0.99)  | 0.0206| 0.89  |
| rs4369899 | miR-4431 | C/T      | 3204       | 0.338| 3285       | 0.316| 0.91|(0.85–0.99)  | 0.0214| 0.89  |
| rs12114358| miR-1206 | G/A      | 3204       | 0.391| 3288       | 0.408| 1.09|(1.01–1.17)  | 0.0273| 0.89  |
| rs1725270 | miR-548x-2| T/C   | 3203       | 0.140| 3286       | 0.150| 1.12|(1.01–1.24)  | 0.0283| 0.89  |
| rs72111449| miR-548h-3| A/C   | 3203       | 0.211| 3288       | 0.196| 0.91|(0.83–0.99)  | 0.0347| 0.89  |
| rs10840491| miR-4686 | T/C      | 3203       | 0.139| 3288       | 0.125| 0.90|(0.81–1.00)  | 0.0447| 0.89  |
| rs7526812 | miR-3117 | C/T      | 3204       | 0.151| 3287       | 0.159| 1.11|(1.00–1.22)  | 0.0456| 0.89  |

| SNP       | Gene    | Alleles† | Controls N | MAF‡ | BE cases N | MAF‡ | OR* | 95% CI       | P     | q     |
|-----------|---------|----------|------------|------|------------|------|-----|--------------|-------|-------|
| rs1043681 | THAP3   | C/T      | 3204       | 0.316| 3288       | 0.301| 0.90|(0.83–0.97)  | 0.0064| 0.89  |
| rs7248876 | ZNF181  | G/A      | 3200       | 0.333| 3286       | 0.357| 1.10|(1.02–1.18)  | 0.0139| 0.89  |
| rs1043420 | CAPN5   | C/T      | 3203       | 0.222| 3288       | 0.236| 1.10|(1.01–1.20)  | 0.0247| 0.89  |
| rs13043447| CABLES2 | T/C      | 3204       | 0.080| 3287       | 0.071| 0.86|(0.76–0.99)  | 0.0324| 0.89  |
| rs1043641 | ACBD3   | A/G      | 3204       | 0.172| 3288       | 0.158| 0.90|(0.82–0.99)  | 0.0331| 0.89  |
| rs1644730 | RDH8    | A/T      | 3199       | 0.473| 3285       | 0.453| 0.93|(0.86–1.00)  | 0.0384| 0.89  |

*nominal P < 0.05
†Minor/major alleles
‡Minor allele frequency
*OR adjusted for sex, PC1-PC4, using additive model (per-allele)

doi:10.1371/journal.pone.0128617.t003
q = 0.057) with BMI in relation to risk of BE, with elevated disease risk seen only among obese individuals.

Discussion

Using genotyping data from a recent consortium-based GWAS, we evaluated the association of 568 miRNA-related SNPs with risks of EA and BE. In total, 29 SNPs were found to be nominally associated (P < 0.05) with risk of EA, and 25 with risk of BE, with three shared variants identified between these analyses. None remained significant after correction for multiple comparisons.

Aberrant expression of miRNAs has been reported in many cancers, and several studies have described miRNA expression changes at specific stages in the development of EA, which may be associated with progression or prognosis [24, 29, 31, 33, 35, 36]. Inherited genetic variation in the miRNA pathway has been linked to altered susceptibility to a variety of cancers, but few studies have focused on esophageal cancer, and in particular, EA (as opposed to esophageal squamous cell carcinoma, ESCC) [39, 40, 70, 71]. The largest previous study included 386 esophageal cancer cases (86% EA, n = 296) [40], and identified seven SNPs significantly associated with cancer risk, five of which were associated specifically with EA. Of those, a single SNP in the pre-miR-423 region remained significant after adjustment for multiple comparisons. This variant failed to validate in our own present study of >2,500 EA cases and >3,200 controls.

Since BE is an established risk factor for, and the only known precursor of, EA, it was of interest to compare the list of SNPs nominally associated with risk of each condition. For each of the three variants reaching P < 0.05 in both analyses (RDH8 rs1644730 T > A, miR-3117 rs7526812 T > C, and miR-4467 rs12534337 G > A), the direction and magnitude of the OR was very similar for BE and EA (S4 Table), raising the possibility that the association with risk of BE might account for the association with risk of EA. However, given our use of a single control group for comparison to both the EA and BE case groups, cautious interpretation is required, since some shared associations could be expected by chance alone. When EA and BE cases were combined into a single case group and compared to the same set of controls, all three of these variants were highly-ranked among the set of 31 nominally significant SNPs (S7 Table), and two of the three (rs7526812 T > C, rs12534337 G > A) had smaller P values than observed in the individual analyses, without reaching Bonferroni or FDR significance thresholds.

rs1644730 T > A is located within a predicted miR-630 binding site in the 3' UTR of all-trans-retinol dehydrogenase 8 (RDH8), which encodes a short-chain dehydrogenase/reductase enzyme involved in rhodopsin regeneration in the vision pathway. Of interest, the enzymatic activity of RDH8 has also been linked to estrogen biosynthesis [72]. Given the significantly higher incidence of BE/EA among males versus females, a potential protective effect of estrogens has been proposed, and some evidence exists for reduced disease risk associated with hormone replacement therapy [73]. An intriguing hypothesis relates to whether the suggested inverse association observed in this study for rs1644730 T > A may reflect impaired miRNA-mediated repression of RDH8 and consequent elevations in estrogen synthesis. In exploratory analyses stratified by sex, the inverse association of this variant with risk of EA appeared stronger among males (OR = 0.86, p = 0.00057, q = 0.23) relative to the overall study sample (OR = 0.88, p = 0.0011, q = 0.54), and was not evident among the limited pool (n = 1200) of female participants (OR = 0.97, p = 0.79). rs12534337 G > A is located in the miR-4467 precursor, identified by deep sequencing of the small RNA transcriptome of normal and malignant B cells, and paired normal and tumor breast tissue (68, 69). Expression of miR-4467 has not been assessed in the esophagus, and no studies have examined functional effects of this miRNA. The proto-oncogene JUNB mRNA is predicted by the TargetScan algorithm to be one of 23
conserved targets of miR-4467, but experimental validation has not been reported. Any influence of this SNP on the biogenesis of miR-4467 remains to be determined. rs7526812 T>C is located ~15kb downstream from, and is in strong linkage disequilibrium ($r^2 = 1.0$) with, a variant in the miR-3117 gene locus (rs12402181). rs7526812 T>C is also a missense polymorphism situated within an exon of the SGIP gene, which has been genetically linked to fat mass [74].

Five of the seven SNPs reported to be associated with risk of esophageal cancer (EA/ESCC) by Ye et al. [40] were included in our analysis of genotyped SNPs from the BEACON GWAS, including their single SNP (pre-miR-423 rs6505162) reported as significant after correction for multiple comparisons. Three of these five SNPs had been associated with EA (miR-423 rs6505162, miR-196a-2 rs11614913, and RAN rs14035), while two reached borderline significance (XPO5 rs11077 and pri-miR-219-1 rs213210). In our study, none of these five SNPs were (nominally) associated ($P<0.05$) with either EA or BE (S8 Table), and nearly all ORs were very close to 1. Ye et al. evaluated three genetic models (additive, recessive, dominant) and reported the best-fitting model in their analysis, in contrast to our approach of assessing exclusively the additive model. Re-analysis of these five SNPs using the alternative models resulted in one polymorphism reaching borderline significance (pri-miR-219-1 rs213210 T>C, dominant model, EA OR 1.17, 95% CI 1.01–1.47, $P = 0.06$), in the same direction as the previously published results (OR 1.61, $P = 0.058$). Ye et al. did not evaluate any of the nominally-associated variants identified in our analysis. Multiple factors could account for discrepancies between studies. First, many apparent signals in association studies may be false positives, and replication in large, independent populations is critical (our EA analysis included more than eight times as many cases as the previous study). Second, different approaches were taken in adjustment for covariates. While both studies included only individuals of European ancestry, we also adjusted for population stratification via inclusion of several PCs derived from principal components analysis, but chose not to adjust for smoking status.

Strengths of our study included the use of pooled data from the BEACON GWAS, which provided the largest sample size to date in the evaluation of miRNA-related SNPs and risks of EA and BE. Inclusion of both BE and EA cases allowed for a comparison of the genetic variation associated with risk of a neoplastic precursor lesion and the cancer that arises from it. The availability of covariate data for smoking history and BMI further enabled us to evaluate gene-environment interactions for two established risk factors for these conditions. Our assessment of 568 polymorphisms significantly expands upon past efforts to examine genetic variation in miRNA pathways in relation to risk of Barrett’s esophagus and esophageal adenocarcinoma. In particular, our inclusion of >120 SNPs within 14 genes implicated in miRNA biogenesis allowed for broad coverage of this canonical core pathway, activity of which underlies the global expression of miRNAs.

This study also had certain limitations. First, while the EA/BE GWAS employed in our analyses represents the largest study of its kind currently available, it remains plausible that among the variants examined, some true associations of small magnitude were missed due to power constraints, especially those present exclusively in population sub-groups. Missing data for smoking/obesity in a fraction of participants further restricted the size of our study sample for stratified analyses and assessment of effect modification. Second, our examination of genetic variation within miRNA gene loci and miRNA-targeted mRNAs was not comprehensive. Of the ~1600 miRNAs deposited in miRBase, only ~200 were represented in our analysis. We used stringent rather than exhaustive inclusion criteria for selecting miRNA-targeted mRNAs for analysis, and prioritized targets for which expression of cognate miRNAs has been reported in esophageal tissue. While this category of variants could have been vastly expanded based on bioinformatic predictions, the majority of such predicted miRNA:mRNA interactions are not validated, and are of unknown biological significance.
In sum, our results do not provide evidence for an association between common genetic variation in components of the miRNA biogenesis core pathway and altered risk of EA or BE. Additional studies may be justified to examine potential associations between unassessed germline variants in miRNA gene loci and miRNA target genes and risk of these conditions. Validation in independent study populations, coupled with functional evaluation of the biological effects of specific SNPs, would be needed to substantiate any polymorphisms as causal risk factors for BE or EA.

Supporting Information
S1 Fig. Selection of miRNA-related SNPs.
(PDF)
S2 Fig. Scree plot of percent variance accounted for versus principal component index.
(PDF)
S3 Fig. Scatter plots of pairwise comparisons among the first four principal components.
(PDF)
S4 Fig. Histograms of P-values obtained from primary logistic regression analyses.
(PDF)
S1 Table. miRNAs reported to be expressed in normal squamous epithelium of the esophagus, BE, dysplastic epithelium, or EA.
(PDF)
S2 Table. MiRNA-related SNPs previously reported to be associated with cancer susceptibility.
(XLSX)
S3 Table. MiRNA-related SNPs selected for analysis.
(XLSX)
S4 Table. Three SNPs from the intersection of Tables 2 & 3, and risk of EA, BE, or [EA/BE].
(PDF)
S5 Table. MiRNA-related SNPs and risk of EA stratified by smoking history or BMI.
(PDF)
S6 Table. MiRNA-related SNPs and risk of BE stratified by smoking history or BMI.
(PDF)
S7 Table. MiRNA-related SNPs and risk of EA/BE.
(PDF)
S8 Table. Five significant miRNA-related SNPs from Ye et al. [40] and risk of EA or BE.
(PDF)

Acknowledgments
We thank Terri Watson, Tricia Christopherson, and Paul Hansen for their contributions in project management and organization of biospecimens/data. We thank Dr. Liam Murray (Queen’s University Belfast, UK) for access to GWAS data derived from subjects enrolled in
his past studies of EA and BE (FINBAR Study). Genotyping data for MD Anderson controls [42] was obtained from dbGaP through accession number phs000187.v1.p1.

Author Contributions
Conceived and designed the experiments: MFB TLV. Analyzed the data: MFB TLV UP DML LO. Wrote the paper: MFB TLV. Participant recruitment: HAR WHC GL RCF LB WY NCB YR AGC DAC NJS AHW MDG BJR LJH DCW TLV. Study supervision: TLV.

References
1. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007; 17: 2–9. PMID: 17185192
2. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett’s oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. Nature Publishing Group; 2010; 10: 87–101. doi: 10.1038/nrc2773 PMID: 20094044
3. Moons LM, Kuipers EJ, Groothuisink AZ, Geldof H, Bode WA, et al. (COX-2) (CA-haplo-type) is a risk factor for the development of esophageal adenocarcinoma. Am J Gastroenterol. 2007; 102: 2373–2379. PMID: 17581270
4. Kristinsson JO, van Westerveld P, te Morsche RH, Roelofs HM, Wobbes T, Witteman BJ, et al. Cyclooxygenase-2 polymorphisms and the risk of esophageal aden- or squamous cell carcinoma. World J Gastroenterol. 2009; 15: 3493–3497. Available: http://www.ncbi.nlm.nih.gov/pubmed/19630103 PMID: 19630103
5. Babar M, Ryan AW, Anderson LA, Segurado R, Turner G, Murray LJ, et al. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma. Am J Gastroenterol. 2012; 107: 1331–1341. doi: 10.1038/aig.2012.134 PMID: 22664470
6. Menke V, van Zoest KP, Moons LM, Hansen B, Pot RG, Siersema PD, et al. [NcoI] [TNF-β] gene polymorphism and (TNF) expression are associated with an increased risk of developing Barrett’s esophagus and esophageal adenocarcinoma. Scand J Gastroenterol. 2012; 47: 378–386. doi: 10.3109/00365521.2011.650192 PMID: 22243485
7. Casson AG, Zheng Z, Porter GA, Guernsey DL. Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma. Cancer Detect Prev. 2006; 30: 423–431. PMID: 17064856
8. Bull LM, White DL, Bray M, Nurgalieva Z, Eli-Serag HB. Phase I and (II) enzyme polymorphisms as risk factors for Barrett’s esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis. Dis Esophagus. 2009; 22: 571–587. doi: 10.1111/j.1442-2050.2009.00947.x PMID: 19222528
9. Di Martino E, Hardie LJ, Wild CP, Gong YY, Olliver JR, Gough MD, et al. The [NAD(P)H:quinone oxi-doreductase I [C609T] polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. Genet Med. 2007; 9: 341–347. PMID: 17575500
10. Doecke J, Zhao ZZ, Pandeya N, Sadeghi S, Stark M, Green AC, et al. Polymorphisms in (MGMT) and (DNA) repair genes and the risk of esophageal adenocarcinoma. Int J Cancer. 2008; 123: 174–180. doi: 10.1002/ijc.23410 PMID: 18386786
11. Zhai R, Liu G, Asomaning K, Su L, Kulke MH, Heist RS, et al. Genetic polymorphisms of (VEGF), interactions with cigarette smoking exposure and esophageal cancer risk. Carcinogenesis. 2008; 29: 2330–2334. doi: 10.1093/carcin/bgn210 PMID: 18780893
12. Cheung WY, Zhai R, Bradbury P, Hopkins J, Kulke MH, Heist RS, et al. Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int J Cancer. 2012;
13. Liu CY, Wu MC, Chen F, Ter-Minassian M, Asomaning K, Zhai R, et al. A Large-scale genetic association study of esophageal adenocarcinoma risk. Carcinogenesis. 2010; 31: 1259–1263. doi: 10.1093/carcin/bgq092 PMID: 20453000
14. Orloff M, Peterson C, He X, Ganapathi S, Heald B, Yang Y, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA. 2011; 306: 410–419. doi: 10.1001/jama.2011.1029 PMID: 21791690
15. Su Z, Gay LJ, Strange A, Palles C, Band G, Whiteman DC, et al. Common variants at the (MHC) locus and at chromosome 16q24.1 predispose to Barrett’s esophagus. Nat Genet. 2012; 44: 1131–1136. doi: 10.1038/ng.2408 PMID: 22961001
16. Levine DM, Ek WE, Zhang R, Liu X, Onstad L, Sather C, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus. Nat Genet. 2013; 45: 1487–93. doi: 10.1038/ng.2796 PMID: 24121790

17. Ek WE, Levine DM, Amato MD, Pedersen NL, Magnusson PKE, Bresso F, et al. Germline Genetic Contributions to Risk for Esophageal Adenocarcinoma, Barrett’s Esophagus, and Gastroesophageal Reflux. J Natl Cancer Inst. 2013; 105: 1711–1718. doi: 10.1093/jnci/djt303 PMID: 24168968

18. Palles C, Chegwidden L, Li X, Findlay JM, Farnham G, Giner FC, et al. Polymorphisms Near TBX5 and GDF7 Are Associated With Increased Risk for Barrett’s Esophagus. Gastroenterology. 2014;

19. Pasquinelli AE. [MicroRNAs] and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012; 13: 271–282. doi: 10.1038/nrg3162 PMID: 22411466

20. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014; 9: 287–314. doi: 10.1146/annurev-pathol-012513-104715 PMID: 24079833

21. Hulsmans M, De Keyzer D, Holvoet P. [MicroRNAs] regulating oxidative stress and inflammation in relation to obesity and atherosclerosis. (FASEB) J. 2011; 25: 2515–2527. doi: 10.1096/fj.11-181149 PMID: 21507901

22. Contreras J, Rao DS. (MicroRNAs) in inflammation and immune responses. Leukemia. 2012; 26: 404–413. doi: 10.1038/leu.2011.356 PMID: 22182919

23. Bansal A, Hong X, Lee I- H, Krishnadath KK, Mathur SC, Gunewardena S, et al. MicroRNA Expression can be a Promising Strategy for the Detection of Barrett’s Esophagus: A Pilot Study. Clin Transl Gastroenterol. Nature Publishing Group; 2014; 5: e65. doi: 10.1038.ctg.2014.17 PMID: 25502391

24. Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, et al. [MicroRNA] expression signatures during malignant progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer Prev Res. 2013; 6: 196–205. doi: 10.1158/1940-6207.CAPR-12-0276 PMID: 23466817

25. Bansal A, Lee IH, Hong X, Mathur SC, Tawfik O, Rastogi A, et al. Discovery and validation of Barrett’s esophagus [microRNA] transcriptome by next generation sequencing. (PLoS) One. 2013; 8: e54240. doi: 10.1371/journal.pone.0054240 PMID: 23372692

26. Saad R, Chen Z, Zhu S, Jia P, Zhao Z, Washington MK, et al. Deciphering the Unique [MicroRNA] Signature in Human Esophageal Adenocarcinoma. (PloS) one. 2013; 8: e64463. doi: 10.1371/journal.pone.0064463 PMID: 23724052

27. Streppel MM, Pai S, Campbell NR, Hu C, Yabuuchi S, Canto MI, et al. microRNA 223 Is Upregulated in the Multistep Progression of Barrett’s Esophagus and Modulates Sensitivity to Chemotherapy by Targeting PARP1. Clin Cancer Res. 2013; 19: 4067–4078. doi: 10.1158/1078-0432.CCR-13-0601 PMID: 23757351

28. Garman KS, Owzar K, Hauser ER, Westfall K, Anderson BR, Souza RF, et al. MicroRNA expression differentiates squamous epithelium from Barrett’s esophagus and esophageal cancer. Dig Dis Sci. 2013; 58: 3178–88. doi: 10.1007/s10620-013-2806-7 PMID: 23925817

29. Revilla-Nuin B, Parrilla P, Lozano JJ, de Haro LFM, Ortiz A, Martinez C, et al. Predictive value of Micro-RNAs in the progression of barrett esophagus to adenocarcinoma in a long-term follow-up study. Ann Surg. 2013; 257: 886–93. doi: 10.1097/SLA.0b013e31826ddba6 PMID: 23059500

30. Sakai NS, Samia-Aly E, Barbera M, Fitzgerald RC. A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol. Elsevier Ltd; 2013; 23: 512–21. doi: 10.1016/j.semcancer.2013.08.005 PMID: 24013023

31. Leidner RS, Ravi L, Leahy P, Chen Y, Bednarchik B, Streppel M, et al. The [MicroRNA]s, (MiR-31) and (MiR-375), as candidate markers in Barrett’s esophageal carcinogenesis. Genes Chromosom Cancer. 2012; 51: 473–479. doi: 10.1002/gcc.21934 PMID: 22302717

32. Fassan M, Volinia S, Palatini J, Pizzi M, Baffa R, De Bernard M, et al. (MicroRNA) expression profiling in human Barrett’s carcinogenesis. Int J Cancer. 2011; 129: 1661–1670. doi: 10.1002/ijc.25823 PMID: 21128279

33. Nguyen GH, Schetter AJ, Chou DB, Bowman ED, Zhao R, Hawkess JE, et al. Inflammatory and (microRNA) gene expression as prognostic classifier of Barrett’s-associated esophageal adenocarcinoma. Clin Cancer Res. 2010; 16: 5824–5834. doi: 10.1158/1078-0432.CCR-10-1110 PMID: 20947516

34. Wijnhoven BP, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ, et al. (MicroRNA) profiling of Barrett’s oesophagus and oesophageal adenocarcinoma. Br J Surg. 2010; 97: 853–861. doi: 10.1002/bjs.7000 PMID: 20301167

35. Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, et al. (MicroRNA) expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 2009; 15: 6192–6200. doi: 10.1158/1078-0432.CCR-09-1467 PMID: 19789312
36. Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, et al. MicroRNA expression signatures in Barrett’s esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009; 15: 5744–52. doi: 10.1158/1078-0432.CCR-09-0385 PMID: 19737949
37. Maru DM, Singh RR, Hannah C, Albarracin CT, Li YX, Abraham R, et al. (MicroRNA-196a) is a potential marker of progression during Barrett’s metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009; 174: 1940–1948. doi: 10.2353/ajpath.2009.080718 PMID: 19342367
38. Feber A, Xi L, Luketch JD, Pennathur A, Landreneau RJ, Wu M, et al. (MicroRNA) expression profiles of esophageal cancer. J Thorac Cardiovasc Surg. 2008; 135: 255–60; discussion 260. doi: 10.1016/j.jtcs.2007.08.055 PMID: 18242245
39. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010; 10: 389–402. doi: 10.1038/nrc2867 PMID: 20495573
40. Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA, et al. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila). 2008; 1: 460–9. doi: 10.1158/1940-6207.CAPR-08-0135 PMID: 19138993
41. Buas MF, Levine DM, Makar KW, Utsumi H, Onstad L, Li X, et al. Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis. 2014; 35: 2740–2747. doi: 10.1046/j.1046-205x.2001.00188.x PMID: 25280564
42. Amos CI, Wang L-E, Lee JE, Gershenson DL, Chen VT, Barnholtz-Sloan JS, et al. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. J Clin Oncol. 2011; 29: 1668–74. doi: 10.1200/JCO.2010.33.3514 PMID: 21482675
43. Nicoloro MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumour susceptibility. Cancer Res. 2010; 70: 2789–98. doi: 10.1158/0008-5472.CAN-09-3541 PMID: 20332227
44. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, et al. Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res. 2010; 70: 9765–76. doi: 10.1158/0008-5472.CAN-10-1303 PMID: 21118967
45. Zhou X, Chen X, Hu L, Han S, Qiang F, Wu Y, et al. Polymorphisms involved in the (miR-218-LAMB3) pathway and susceptibility of cervical cancer, a case-control study in Chinese women. Gynecol Oncol. 2010; 117: 287–290. doi: 10.1016/j.ygyno.2010.01.020 PMID: 20163849
46. Lin J, Chen H, Shi J, Zhang Y, Duan X, Wang S, et al. Association of a common (AGO1) variant with lung cancer risk: a two-stage case-control study. Mol Carcinog. 2010; 49: 913–921. doi: 10.1002/mc.20672 PMID: 20718045
47. Zhang X, Yang H, Lee JJ, Kim E, Lippman SM, Khuri FR, et al. (MicroRNA-related) genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis. 2010; 31: 2118–2123. doi: 10.1093/carcin/bgp177 PMID: 20819778
48. Chen AX, Yu KD, Fan L, Li JY, Yang C, Huang AJ, et al. Germline variant analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis. 2011; 32: 1668–1674. doi: 10.1093/carcin/bgr209 PMID: 21934093
49. Liu Z, Wei S, Ma H, Zhao M, Myers JN, Weber RS, et al. A functional variant at the (miR-184) binding site in (TNFAIP2) and risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2011; 32: 1668–1674. doi: 10.1093/carcin/bgr209 PMID: 21934093
50. Permuth-Wey J, Kim D, Tsai Y, Lin H-Y, Chen YA, Bambholt-Sloan J, et al. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res. 2011; 71: 3896–903. doi: 10.1158/0008-5472.CAN-10-4167 PMID: 21482675
51. Reshmi G, Surya R, Jissa VT, Babu PS, Preethi WS, Santhi WS, et al. C-T variant in a (miRNA) target site of (BCL2) is associated with increased risk of human papilloma virus related cervical cancer—an in silico approach. Genomics. 2011; 98: 189–193. doi: 10.1016/j.ygeno.2011.06.005 PMID: 21704150
52. Xiong F, Wu C, Chang J, Yu D, Xu B, Yuan P, et al. Genetic variation in an (miRNA-1827) binding site in (MYCL1) alters susceptibility to small-cell lung cancer. Cancer Res. 2011; 71: 5175–5181. doi: 10.1158/0008-5472.CAN-10-4407 PMID: 21676885
57. Sung H, Lee KM, Choi JY, Han S, Lee JY, Li L, et al. Common genetic polymorphisms of (microRNA) biogenesis pathway genes and risk of breast cancer: a case-control study in Korea. Breast Cancer Res Treat. 2011; 130: 939–951. doi:10.1007/s10549-011-1656-2 PMID: 21766210

58. Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of (miR-34b/c) is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 2011; 128: 412–417. doi:10.1002/ijc.20399 PMID: 20309624

59. Zhang L, Liu Y, Song F, Zheng H, Hu L, Lu H, et al. Functional (SNP) in the (microRNA-367) binding site in the (3'UTR) of the calcium channel ryanodine receptor gene 3 ((RYR3)) affects breast cancer risk and calcification. Proc Natl Acad Sci U S A. 2011; 108: 13653–13658. doi:10.1073/pnas.110360108 PMID: 21810988

60. Zhong H, Song F, Zhang L, Yang D, Ji P, Wang Y, et al. Genetic variants at the (miR-124) binding site on the cytoskeleton-organizing (IQGAP1) gene confer differential predisposition to breast cancer. Int J Oncol. 2011; 38: 1153–1161. doi:10.3892/ijo.2011.940 PMID: 21318219

61. Bae JS, Kim JH, Pasaje CF, Cheong HS, Lee TH, Koh IS, et al. Association study of genetic variations in (microRNAs) with the risk of hepatitis B-related liver diseases. Dig Liver Dis. 2012; 62.

62. Liu Y, Zhang Y, Wen J, Liu L, Zhai X, Liu J, et al. A genetic variant in the promoter region of (miR-106b-25) cluster and risk of (HBV) infection and hepatocellular carcinoma. (PLoS) One. 2012; 7: e32230. doi: 10.1371/journal.pone.0032230 PMID: 22393390

63. Teo MT, Landi D, Taylor CF, Elliott F, Vaslin L, Cox DG, et al. The role of (microRNA-binding) site polymorphisms in (DNA) repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes. Carcinogenesis. 2012; 33: 581–586. doi: 10.1093/carcin/bgr272 PMID: 22114071

64. Yang L, Li Y, Cheng M, Huang D, Zheng J, Liu B, et al. A functional polymorphism at (microRNA-629-binding) site on the 3'-untranslated region of (NBS1) gene confers an increased risk of lung cancer in Southern and Eastern Chinese population. Carcinogenesis. 2012; 33: 338–347. doi:10.1093/carcin/bgr272 PMID: 22114071

65. Guo H, Wang K, Xiong G, Hu H, Wang D, Xu X, et al. A functional varient in (microRNA-146a) is associated with risk of esophageal squamous cell carcinoma in Chinese Han. Fam Cancer. 2010; 9: 599–603. doi:10.1007/s10689-010-9370-5 PMID: 20680470

66. Wang K, Guo H, Hu H, Xiong G, Guan X, Li J, et al. A functional variation in pre-(microRNA-196a) is associated with susceptibility of esophageal squamous cell carcinoma in Chinese Han. Biomarkers. 2010; 15: 614–618. doi:10.3109/1354750X.2010.505299 PMID: 20722507

67. Lee YH, Kim J-H, Song GG. Pathway analysis of a genome-wide association study in schizophrenia. Gene. 2013; 525: 107–115. doi: 10.1016/j.gene.2013.04.014 PMID: 23644028

68. Lagergren K, Lagergren J, Brusselaers N. Hormone replacement therapy and oral contraceptives and risk of oesophageal adenocarcinoma: A systematic review and meta-analysis. Int J Cancer. 2014; 135: 2183–90. doi: 10.1002/ijc.28869 PMID: 24676860

69. Cummings N, Shields KA, Curran JE, Bozaoglu K, Trevaskis J, Gluschenko K, et al. Genetic variation in SH3-domain GRB2-like (endophilin)-interacting protein 1 has a major impact on fat mass. Int J Obes (Lond). 2012; 36: 201–6. doi: 10.1038/ijo.2011.67 PMID: 21407171